01.08.2021 | Tracker

Product Launch Tracker: HCPs celebrate Merck & Co and Bayer approvals, while discussing Moderna’s extension at length

By Aaron Pitkin

Product Launch Tracker: HCPs celebrate Merck & Co and Bayer approvals, while discussing Moderna’s extension at length

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout July 2021 we tracked the global conversations of over 3,000 HCPs who posted more than 4,800 English-language Twitter posts in relation to product approvals.

An image of a graph showing HCP mentions of product launches on Twitter in July 2021

In July 2021, the new product approvals that caught HCPs’ attention were Merck & Co’s KEYTRUDA® (pembrolizumab), triple negative breast cancer treatment (TNBC) treatment, Bayer Healthcare’s Kerendia (finerenone) treatment to reduce the risk of eGFR decline, end stage kidney disease, cardiovascular death & non-fatal myocardial infarction in adult patients with chronic kidney disease (CKD) with type 2 diabetes (T2D), and Moderna’s Spikevax, COVID-19 vaccine for children from the ages of 12.

Several HCPs, such as Medical Oncologist and Hematologist, Dr Hope Rugo, celebrated the FDA approval of KEYTRUDA® (pembrolizumab) for patients with high-risk early-stage triple negative breast cancer (TNBC), stating that it was a “big step for patients with TNBC” and “great news for [their] patients”.

Some HCPs, such as, Nephrologists, Dr Mario AL S and Dr Swapnil Hiremath shared their positive surprise towards Kerendia’s (finerenone) “quick” FDA approval, while over 100 HCPs shared the EMA’s post announcing it’s approval of Spikevax to children from the ages of 12 in Europe.

The three most shared links from HCPs discussing product launches in July were:

An image showing key topics HCPs discussed in july 2021

Throughout the month, the EMA’s approval of Spikevax for children aged 12 and above was a key discussion among HCPs, with over 800 HCP mentions of the vaccine.

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.


  • Using CREATION Pinpoint®, the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 July and 31 July 2021 were analysed.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 July and 31 July 2021, there were 4,871 HCP mentions of new pharmaceutical product launches and drug approvals from 3,099 unique HCP authors from around the world. 

The Product Launch tracker archive

June 2021: HCPs optimistic over Novo Nordisk and Roche approvals but still to be won over by Biogen’s aducanumab




View all articles >

Meet the Author

Aaron Pitkin

Suggested next

01.12.2021 | Article

Product Launch Tracker: HCPs welcome approvals for MSD’s Keytruda and Takeda’s Livtencity

Discover which new drug approvals HCPs are talking about

By Paul Cranston and Tomi Shobande

29.07.2022 | Article

HCPs use Twitter to improve clinical trial design, recruitment and equity

While a field of its own, clinical trial design and recruitment can present a number of...

By Mary Kangley

View all articles >